Skip to main content

Nurtec ODT News

FDA Approves Biohaven's Nurtec ODT (rimegepant) for Preventative Treatment of Migraine

Nurtec ODT 75 mg is the first oral CGRP antagonist approved to prevent migraine Nurtec ODT 75 mg is now the only migraine medication approved to both treat acute migraine attacks and help prevent...

FDA Approves Nurtec ODT (rimegepant) for the Acute Treatment of Migraine in Adults

NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ – Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved Nurtec ODT...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Migraine Prevention, Migraine Prophylaxis, Migraine

Nurtec ODT patient information at Drugs.com